Nimodipine Shortage Update: What Patients Need to Know in 2026

If you've been prescribed nimodipine after a subarachnoid hemorrhage and are having trouble filling your prescription, you need up-to-date information — not generic advice. The availability of nimodipine in the U.S. has been complicated in recent years by a combination of a manufacturer formulation change and broader pharmaceutical supply chain issues. Here's what the situation looks like in 2026 and what it means for you.

Current Shortage Status: What the FDA and ASHP Say

As of 2026, the FDA lists Nymalize (nimodipine) oral solution as currently in shortage. The ASHP (American Society of Health-System Pharmacists) has published guidance noting that older Nymalize formulations — including 10 mL unit-dose cups, 20 mL unit-dose cups, and the 473 mL pint bottle — have been discontinued by Arbor Pharmaceuticals.

Arbor Pharmaceuticals has transitioned Nymalize to a new formulation: 5 mL prefilled oral syringes at a concentration of 6 mg/mL (30 mg per syringe). While this formulation is available, the transition period has created disruption in the supply chain, contributing to the ongoing shortage.

The generic nimodipine 30 mg oral capsule is NOT in shortage at the national level, though localized stocking gaps can occur at individual pharmacies, especially smaller retail chains and independent pharmacies that don't regularly stock low-volume medications.

What Is Causing the Nimodipine Shortage?

Several factors have combined to create availability challenges for nimodipine in 2026:

1. Formulation transition: Arbor Pharmaceuticals discontinued multiple older Nymalize formats and transitioned to prefilled oral syringes. During this changeover, supply dropped before the new inventory fully reached hospitals and pharmacies.
2. Safety-driven packaging changes: Deaths caused by the accidental IV injection of nimodipine liquid (drawn from capsules and mistakenly administered intravenously) prompted the FDA and manufacturers to redesign packaging with new safety features — slowing production timelines.
3. Low-volume niche market: Subarachnoid hemorrhage affects approximately 30,000 Americans per year, making nimodipine a relatively low-volume medication. This means fewer manufacturers, thinner supply buffers, and greater vulnerability to disruption.
4. Generic supply fragility: Patent expiration has led to generic competition, but the number of generic manufacturers is still limited. Any production hiccup from one manufacturer ripples across the market.

Which Nimodipine Products Are Affected?

Here is a breakdown of the current status for each major nimodipine product:

• Nymalize 3 mg/mL oral solution (old formulation, various cup/bottle sizes): Discontinued by Arbor Pharmaceuticals.
• Nymalize 6 mg/mL oral solution (new prefilled syringe): Available from Arbor Pharmaceuticals, but supply has been intermittently limited; currently listed in FDA shortage.
• Generic nimodipine 30 mg oral capsules: Generally available nationally; may have localized gaps at individual pharmacies.

What Can Patients Do During the Nimodipine Shortage?

The most important action is to not stop taking nimodipine on your own. The treatment window is 21 days, and vasospasm risk is highest in the first two weeks after a subarachnoid hemorrhage. Here's what to do if your prescription can't be filled:

• Contact your neurology team or neurosurgeon immediately — they can help coordinate sourcing.
• Ask your doctor if switching from Nymalize solution to generic nimodipine capsules is appropriate for your situation.
• Use medfinder to search for pharmacies with nimodipine in stock — medfinder contacts pharmacies on your behalf and texts you which ones have it available.
• Try hospital outpatient pharmacies and specialty pharmacies, which tend to stock nimodipine more reliably than retail chains.

Looking Ahead: Will the Shortage Resolve?

The generic capsule supply is relatively stable and should remain available with some diligence in finding a stocking pharmacy. The Nymalize oral solution shortage is tied to the formulation transition, and Arbor's new prefilled syringe product is on the market — meaning the pathway to resolution exists. However, given nimodipine's niche status and the ongoing fragility of generic drug supply chains in the U.S., periodic localized shortages are likely to continue.

Related: How to Find Nimodipine in Stock Near You (Tools + Tips).